Sodium Thiosulfate in Acute Myocardial Infarction: A Randomized Clinical Trial

Marie Sophie L.Y. de Koning, Paulien van Dorp, Solmaz Assa, Gabija Pundziute-Do Prado, Michiel Voskuil, Rutger L. Anthonio, Duco Veen, Tim Leiner, Anita J. Sibeijn-Kuiper, Harry van Goor, Dirk J. van Veldhuisen, Peter van der Meer, Robin Nijveldt, Erik Lipšic, Pim van der Harst*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

9 Downloads (Pure)


In this proof-of-principle trial, the hypothesis was investigated that sodium thiosulfate (STS), a potent antioxidant and hydrogen sulfide donor, reduces reperfusion injury. A total of 373 patients presenting with a first ST-segment elevation myocardial infarction received either 12.5 g STS intravenously or matching placebo at arrival at the hospital and 6 hours later. The primary outcome, infarct size, measured by cardiac magnetic resonance at 4 months after randomization, did not differ between the treatment arms. Secondary outcomes were comparable as well, suggesting no clinical benefit of STS in this population at relatively low risk for large infarction.

Original languageEnglish
Pages (from-to)1285-1294
Number of pages10
JournalJACC: Basic to Translational Science
Issue number10
Publication statusPublished - Oct 2023


  • clinical trial
  • hydrogen sulfide
  • ischemia-reperfusion injury
  • myocardial infarction
  • randomized controlled trial
  • thiosulfates


Dive into the research topics of 'Sodium Thiosulfate in Acute Myocardial Infarction: A Randomized Clinical Trial'. Together they form a unique fingerprint.

Cite this